BRIEF-Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.